RIPE-KG · Version 1.1.0 · Resource
ripekg:retraction-notice/50503
https://w3id.org/ripe/ripe-kg/retraction-notice/50503
| Subject | Predicate | Object |
|---|---|---|
ripekg:evaluation/RIPEA0A4B2238CEE31171 |
prov:used |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
prism:doi |
10.3389/fonc.2023.1337635 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
prism:publicationDate |
2023-12-07 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
prism:publicationName |
Frontiers in Oncology |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
dcterms:publisher |
ripekg:publisher/RIPEP6D94DBCE26C24120Frontiers |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
dcterms:title |
Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
http://purl.org/spar/cito/retracts |
ripekg:work/10.3389%2Ffonc.2020.588533 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
rdf:type |
http://purl.org/spar/fabio/RetractionNotice |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
rdf:type |
rdfs:Resource |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
rdf:type |
owl:Thing |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
rdf:type |
ripe:RetractionNoticeRetraction notice |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
rdf:type |
tido:Evidence |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
rdf:type |
tido:PieceOfInformation |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
owl:sameAs |
https://semopenalex.org/work/W4389482723 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
prov:wasAttributedTo |
ripekg:source/retraction-watchRetraction Watch |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
prov:wasAttributedTo |
ripekg:source/retraction-watchRetraction Watch Database |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA0A4B2238CEE31171 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA0A4B2238CEE31171 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
ripe:concerns |
ripekg:author/RIPEAU7E20227A643F80C5Lei Zhang |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
ripe:concerns |
ripekg:work/10.3389%2Ffonc.2020.588533 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
ripe:rationale |
Error in Data;Investigation by Journal/Publisher;Results Not Reproducible;Unreliable Results and/or Conclusions;Upgrade/Update of Prior Notice(s) |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
ripe:retractionWatchRecordId |
50503 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA0A4B2238CEE31171-human-1-3 |
ripekg:retraction-notice/50503Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA0A4B2238CEE31171-inspectai-1-3 |